The basic rational is that the stabilized form of chemokines that induce Tr1-like cells, among them CXCL12 and CXCL11, could be used for therapy of autoimmunity and GVHD, whereas stabilized CXCL10 would be used for cancer therapy. This evidence concerns the gene CXCL10 and cancer.